A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer

NCT06888921 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Cancer
Ovarian Cancer Recurrent

Interventions

DRUG: COM701
DRUG: Normal Saline

Sponsor

Compugen Ltd